SCHEMBL1422916

SCHEMBL1422916

Fc1ccc2[nH]c(-c3ccc(-n4ccnc4)nc3)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.45
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 1/20 0.44
PIM1 P11309 1/20 0.40
IDO1 P14902 3/20 0.39
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
MAPT P10636 1/20 0.38
VCP P55072 1/20 0.37
CYP19A1 P11511 3/20 0.37
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
TRPA1 O75762 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1422837 0.87 CDK5 (0.52) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1484209 0.87 CYP19A1 (0.46) CYP1A2CYP3A4CYP2D6PIM1IDO1
SCHEMBL1483709 0.87 GAA (0.42) CYP1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL13577804 0.87 PIM1 (0.40) CYP1A1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL1424611 0.84 MAPT (0.49) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1483693 0.84 CYP19A1 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19PIM1
SCHEMBL1484074 0.80 GAA (0.42) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1422658 0.80 PIM1 (0.40) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL13577817 0.80 PIM1 (0.40) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL1484070 0.79 CYP1A1 (0.45) CYP1A1PIM1IDO1MAPTCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US claimed
EP-2296474-A1 NOVEL SUBSTITUTED INDOLES Merck Sharp & Dohme Corp. (US) 2011-03-23 EP claimed
WO-2009155024-A1 NOVEL SUBSTITUTED INDOLES MERCK & CO., INC. (US) 2009-12-23 WO claimed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed
US-20110076230-A1 Novel Substituted Indoles MERCK & CO. INC. 2011-03-31 US disclosed
WO-2009155024-A1 NOVEL SUBSTITUTED INDOLES MERCK & CO., INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076230-A1 Novel Substituted Indoles APP, BACE1, PSEN1 CYP1A1 1246/4885CYP1A2 1001/4885CYP3A4 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.